Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Innovative Industrial Properties

AT&T

Collect monthly income even though these stocks pay quarterly. Yes, you read that right.

3 Dividend Stocks That Can Generate Monthly Income for Your Portfolio

iShares Core U.S. Aggregate Bond ETF

iShares 7-10 Year Treasury Bond ETF

Microsoft

SPDR S&P 500 ETF Trust

Verizon

The once standard 60/40 portfolio (e.g. 60% stocks and 40% bonds) is far less appealing to many investors than it used to be - simply because bond yields are so unattractively low. Stocks and bonds are fundamentally different investment types, but if it's simply safe steady income you seek, it may behoove you to consider certain blue chips in lieu of bonds.

Forget Bonds, Try These Blue-Chip Stocks Instead

Apple

Amazon

Alibaba

Salesforce

NIKE

Procter & Gamble

One thing is clear in today's markets, big caps are the smart play, whether as safe harbor in a storm or growth plays on bull markets. The post 7 Hot Stocks To Buy With Mega-Cap Status appeared first on InvestorPlace.

7 Hot Stocks To Buy With Mega-Cap Status

Cisco Systems

Chevron

DouYu International Holdings Ltd

Honeywell

Intel

UnitedHealth Group

Walmart

Two new sample breakout stocks for Week 45 with better than 10% short-term upside potential. Now up an average +244.3% YTD. This past week no stocks gained over 10% and the Momentum Gauge® turned negative Monday in a strong warning signal of market declines. CCRN gained +10.1% on Friday.

Week 45 MDA Breakout Forecast - November: Short-Term Picks To Give You An Edge

AmerisourceBergen

Arrow Financial

Chubb

Enbridge

Enterprise Products Partners

Essex Property Trust

Kimberly-Clark

Altria

Northrop Grumman

Philip Morris

Sanofi

UMB Financial

The pandemic is out of control all over the world, with daily records in new cases and a mounting death toll. Europe is beginning to lock down again and IHME expects up to 20 US states to follow suit starting in late November.

15 High-Yield/Low Volatility Blue Chips For The Ultimate Crash-Proof Retirement Portfolio

Durban-based Aspen Pharmacare Holdings (OTC: APNHY) has preliminary agreed to commercially manufacture Pharmaceutical giant Johnson & Johnson's (NYSE: JNJ) COVID-19 vaccine candidate, Ad26.COV2-S, the company said in a statement. What Happened: According to Bloomberg, Aspen Pharmacare is Africa's biggest drugmaker and can produce 300 million doses a year.

Johnson & Johnson Strikes COVID-19 Vaccine Manufacturing Deal With South Africa's Aspen

Boeing

Dow Inc

Goldman Sachs

JPMorgan Chase & Co

Coca-Cola

Merck

Walgreens

"The Dow® [adds a stock] if the company has an excellent reputation, demonstrates sustained growth, and is of interest to a large number of investors. Sector representation.is also a consideration."- DowJones&Co. 30 Dow stocks represent nine of 11 sectors. Dow tracks utilities as a separate index and omits real estate. Broker top 10 target estimated net gains ranged from 22.21%-47.29% topped by CVX 10/29/20.

4 Dogs Of The Dow Break Out And 3 Break Down In November

South African pharmaceutical company Aspen Pharmacare said on Monday it had entered into a preliminary agreement with Johnson & Johnson to commercially manufacture its COVID-19 vaccine candidate.

South Africa's Aspen agrees with J&J to manufacture COVID-19 vaccine candidate

Johnson & Johnson, normally a defensive stock, has fallen more than the S&P 500 during this downturn. That creates a potentially good opportunity for long-term investors to lock in some very attractive volatility-adjusted returns.

Johnson & Johnson: The Ultimate Retirement Super SWAN Is Now On Sale

AstraZeneca

Pfizer

No, the familiar "this will only sting a little" you hear from healthcare providers isn't one of them.

3 Things About Coronavirus Vaccines That You Almost Certainly Won't Like

Gilead Sciences

Moderna

Update on the COVID Vaccine Race

Colgate-Palmolive

Lockheed Martin

In times of economic recession, investors should prioritize dividend safety. Instead of buying stocks with the highest yields, it makes sense to focus on quality, asserts Ben Reynolds, editor of the just-launched Sure Passive Income newsletter.

4 High-Quality Stocks To Buy & Hold Forever

Cantel Medical

STERIS

COVID-19 has heightened the demand for companies that specialize in infection control.

3 Surefire Stocks to Watch In The Coronavirus Pandemic

Some things have changed, but others haven't.

AstraZeneca and J&J Resume Late-Stage Trials: How It Shakes Up the Coronavirus Vaccine Race

Johnson & Johnson's stock lost more than 23% – dropping from $146 at the beginning of the year to below $112 in late March – then spiked 30% to around $145 now. That means it has fully recovered to the levels where it started the year.

Johnson & Johnson Stock Looks Attractive At $145

BioNTech SE

CureVac B.V

The World Health Organization is managing a global vaccine program without U.S. participation, and it could have a big impact for investors.

Investors Betting on a Coronavirus Vaccine Better Know Who Gets First Dibs in Global Pact

News for Johnson & Johnson Stock (JNJ)